Singapore markets open in 6 hours 2 minutes
Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,300.34 +53.66 (+1.02%) Dow
39,832.17 +274.06 (+0.69%) Nasdaq
16,728.00 +216.82 (+1.31%) Bitcoin USD
65,507.65 +4,119.00 (+6.71%) CMC Crypto 200
1,380.97 +113.02 (+8.91%)
Verrica Pharmaceuticals Inc. (VRCA)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 02:57PM EDT. Market open.
| Previous close | 9.49 |
| Open | 9.50 |
| Bid | 9.29 x 200 |
| Ask | 9.44 x 100 |
| Day's range | 9.27 - 9.95 |
| 52-week range | 2.86 - 11.41 |
| Volume | |
| Avg. volume | 185,083 |
| Market cap | 401.263M |
| Beta (5Y monthly) | 1.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.77 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.83 |
GlobeNewswireVerrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a minimal impact on Verrica’s cash position Common warts is one of the largest and most underserved patient populations in medical dermatology with a prevalence of ~22M in the U.S. and no FDA approved products; Verrica believes com
- GuruFocus.com
Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Explore Verrica Pharmaceuticals' financial performance, strategic partnerships, and operational insights from the first quarter of 2024.
GuruFocus.comVerrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review
Exploring Verrica's Financial Outcomes and Strategic Developments in the First Quarter
© 2024 Yahoo. All rights reserved.